Monalizumab vs Zimistobart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: NKG2A · full Non-Small Cell Lung Cancer pipeline
Monalizumab
Developed by MedImmune LLC and partners
NCT03822351 · Phase 2 · completed
Participants were randomized among three treatment arms, including 62 receiving durvalumab plus monalizumab and 67 receiving durvalumab alone, but the study was open-label rather than blinded. The primary clinical endpoint, RECIST 1.1 objective response at 16 weeks, was 40.3% with monalizumab plus durvalumab versus 23.9% with durvalumab alone; because statistical significance for this comparison was not reported, the result is considered unclear.
Next expected readout: January 2027 · NCT05221840 (registry estimate)
Reported efficacy
Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint): Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint): Control Arm (Durvalumab Monotherapy) 23.9% (95% CI 14.3-35.9) vs Arm A (Durvalumab + Oleclumab) 35.0% (95% CI 23.1-48.4) vs Arm B (Durvalumab + Monalizumab) 40.3% (95% CI 28.1-53.6) (unclear)
Result source: NCT03822351
Zimistobart
Developed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Monalizumab | Zimistobart |
|---|---|---|
| PFS, median | 19.8 vs 7.3vs Durvalumab MonotherapyNCT03822351 | —Not reported |
| OS, median | —Trial running · NCT05221840 | —Not reported |
| ORR | 40.3% vs 23.9%vs Durvalumab MonotherapyNCT03822351 | —Not reported |
| Duration of response, median | 23NCT03822351 | —Not reported |
PFS, median
- Monalizumab
- 19.8 vs 7.3vs Durvalumab MonotherapyNCT03822351
- Zimistobart
- —Not reported
OS, median
- Monalizumab
- —Trial running · NCT05221840
- Zimistobart
- —Not reported
ORR
- Monalizumab
- 40.3% vs 23.9%vs Durvalumab MonotherapyNCT03822351
- Zimistobart
- —Not reported
Duration of response, median
- Monalizumab
- 23NCT03822351
- Zimistobart
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Zimistobart: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Monalizumab: 3 of 4 rows · Zimistobart: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Monalizumab |
|---|---|
| Dropout rate | 51.6%Arm B (Durvalumab + Monalizumab)a NCT03822351 · Phase 2 · combination show 3 more results—Durvalumab + Monalizumab NCT03822351 · Phase 2 · combination 3.7%1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence 5%1500 mg + 750 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —Arm B (Durvalumab + Monalizumab)a NCT03822351 · Phase 2 · combination show 3 more results—Durvalumab + Monalizumab NCT03822351 · Phase 2 · combination —1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence —1500 mg + 750 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | —Arm B (Durvalumab + Monalizumab)a NCT03822351 · Phase 2 · combination show 3 more results27.9%Durvalumab + Monalizumab NCT03822351 · Phase 2 · combination 11.5%1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence 5%1500 mg + 750 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | show 2 more results1500 mg fatigue 23.1% procedural pain 19.2% asthenia 11.5% NCT03794544 · Phase 2 · registry result, not featured evidence 1500 mg + 750 mg constipation 10% fatigue 10% pruritus 10% NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Monalizumab
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Monalizumab's landscape · Zimistobart's landscape